153 related articles for article (PubMed ID: 7138747)
1. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Pike E; Lunde PK
Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
[TBL] [Abstract][Full Text] [Related]
2. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
[TBL] [Abstract][Full Text] [Related]
3. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
Takahashi H; Tamura A; Ogata H; Masuhara K
J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
[TBL] [Abstract][Full Text] [Related]
5. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
Aitio ML
Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
[TBL] [Abstract][Full Text] [Related]
7. A simple method for the simulation of unbound serum disopyramide concentration in patients.
Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
[TBL] [Abstract][Full Text] [Related]
8. [Accumulation of a disopyramide metabolite in renal failure].
Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
[TBL] [Abstract][Full Text] [Related]
9. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
Haughey DB; Lima JJ
Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
Shaw LM; Doherty JU; Waxman HL; Josephson ME
Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of a disopyramide metabolite in renal failure.
Inagaki Y; Amano I; Otsu T
ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in human plasma by capillary electrophoresis.
Jabor VA; Lanchote VL; Bonato PL
Electrophoresis; 2001 Apr; 22(7):1406-12. PubMed ID: 11379964
[TBL] [Abstract][Full Text] [Related]
15. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
16. Disopyramide concentrations in saliva.
Aitio ML; Virtanen R; Lammintausta R
Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
[TBL] [Abstract][Full Text] [Related]
19. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
Haughey DB; Steinberg I; Lee MH
J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
[TBL] [Abstract][Full Text] [Related]
20. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
Lima JJ; Boudoulas H; Blanford M
J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
